Recombinant Vaccinia Virus (strain Western Reserve) Scaffold protein D13

Product Overview

This item requires custom production and lead time is between 4-12 weeks. We can custom produce based on your specifications.

Nature

Recombinant

Tag/Conjugate

TBD

Purity

> 85% as determined by SDS-PAGE

Format

Liquid or Lyophilized powder

Storage

Store at -20°C/-80°C upon receipt. Avoid repeated freeze-thaw cycles.
The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.

Introduction

Smallpox was an infectious disease unique to humans, caused by either of two virus variants, Variola major and Variola minor. The disease is also known by the Latin names Variola or Variola vera, which is a derivative of the Latin varius, meaning "spotted", or varus, meaning "pimple". The term "smallpox" was first used in Britain in the 15th century to distinguish variola from the "great pox" (syphilis). The last naturally occurring case of smallpox (Variola minor) was diagnosed on 26 October 1977.

Function

Scaffold protein which forms a transitory spherical honeycomb lattice providing curvature and rigidity to the convex membrane of crescent and immature virions (IV). This association occurs concomitantly with viral membrane formation. Targeted by the drug rifampicin, which prevents the formation of this lattice, and hence virus morphogenesis. In the presence of rifampicin, irregularly shaped membranes that lack the honeycomb layer accumulate around areas of electron-dense viroplasm. This layer is lost from virions during maturation from IV to mature virion (MV), through the proteolysis of OPG158 N-terminus.

Keywords

Vaccinia Virus Scaffold protein OPG125; 62 kDa protein; Rifampicin resistance protein; D13L; VACWR118; VACV